Agenus, Inc. (AGEN)
8.245
+0.16
(+1.92%)
USD |
NASDAQ |
Sep 03, 16:00
8.245
0.00 (0.00%)
After-Hours: 17:55
Agenus Research and Development Expense (Annual) : 79.34M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 79.34M |
| December 31, 2024 | 155.53M |
| December 31, 2023 | 234.57M |
| December 31, 2022 | 186.69M |
| December 31, 2021 | 178.61M |
| December 31, 2020 | 142.62M |
| December 31, 2019 | 168.34M |
| December 31, 2018 | 124.60M |
| December 31, 2017 | 116.13M |
| December 31, 2016 | 94.97M |
| December 31, 2015 | 57.24M |
| December 31, 2014 | 22.35M |
| December 31, 2013 | 13.01M |
| December 31, 2012 | 9.264M |
| December 31, 2011 | 11.02M |
| Date | Value |
|---|---|
| December 31, 2010 | 12.25M |
| December 31, 2009 | 16.86M |
| December 31, 2008 | 20.66M |
| December 31, 2007 | 21.79M |
| December 31, 2006 | 28.64M |
| December 31, 2005 | 47.08M |
| December 31, 2004 | 41.72M |
| December 31, 2003 | 48.42M |
| December 31, 2002 | 39.70M |
| December 31, 2001 | 31.36M |
| December 31, 2000 | 17.58M |
| December 31, 1999 | 10.98M |
| December 31, 1998 | 6.102M |
| December 31, 1997 | 2.563M |
| December 31, 1996 | 2.017M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Novavax, Inc. | 336.82M |
| Amgen, Inc. | 6.974B |
| Anika Therapeutics, Inc. | 25.77M |
| BioCryst Pharmaceuticals, Inc. | 164.74M |
| Imunon, Inc. | 7.781M |